GERMAN BENEFIT ASSESSMENT IN THE FIELD OF ONCOLOGY: FACTORS INFLUENCING THE BENEFIT RATING IN ADDITION TO COMPLYING WITH THE APPROPRIATE COMPARATOR

被引：0
|
作者：
Ulrich, S. [1 ]
Damen, D. [1 ]
Templin, C. [1 ]
Kulp, W. [1 ]
机构：
[1] Xcenda GmbH, Hannover, Germany
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN386
引用
收藏
页码：S511 / S511
页数：1
相关论文
共 17 条
  • [1] GERMAN AMNOG BENEFIT ASSESSMENT: THE TYPE OF APPROPRIATE COMPARATOR MAKES THE DIFFERENCE
    Templin, C.
    Billig, S.
    Damen, D.
    Kulp, W.
    VALUE IN HEALTH, 2017, 20 (09) : A461 - A462
  • [2] APPROPRIATE COMPARATOR IN GERMAN AMNOG BENEFIT ASSESSMENTS IN MELANOMA - A DYNAMIC SITUATION
    Italia, N.
    Kossow, S.
    Claes, A.
    Templin, C.
    Kulp, W.
    VALUE IN HEALTH, 2018, 21 : S66 - S66
  • [3] GUIDELINES IN GERMAN EARLY BENEFIT ASSESSMENT - WHICH GUIDELINES ARE CONSIDERED BY FEDERAL JOINT COMMITTEE FOR DETERMINING THE APPROPRIATE COMPARATOR?
    Scheler, E.
    Stratil, A.
    Roxlau, T.
    Bonduelle, D.
    VALUE IN HEALTH, 2018, 21 : S197 - S197
  • [4] "BEST SUPPORTIVE CARE" OR "THERAPY ACCORDING TO PHYSICIAN'S CHOICE" AS APPROPRIATE COMPARATOR FOR GERMAN HTA DOSSIERS - AN UNDERESTIMATED CHANCE OR RISK FOR THE BENEFIT ASSESSMENT?
    Eheberg, D.
    Dannemann, S.
    Jakovac, M.
    Bonduelle, D.
    VALUE IN HEALTH, 2016, 19 (07) : A494 - A494
  • [5] A critical assessment of factors influencing the perceived professional benefit of internet nurses
    Li, Xiaoxu
    Zhu, Yichang
    Yang, Bo
    Wu, Bing
    Wang, Meixiang
    Zhao, Yun
    PRECISION MEDICAL SCIENCES, 2021, 10 (03): : 106 - 112
  • [6] ANALYSIS OF FACTORS INFLUENCING THE LEVEL OF ACTUAL BENEFIT IN HEALTH TECHNOLOGY ASSESSMENT
    Bouschon, M.
    Li, J.
    Barthelemy, C.
    VALUE IN HEALTH, 2017, 20 (09) : A401 - A401
  • [7] IS NO THERAPY A THERAPY? EFFECTS OF WATCHFUL WAITING AS APPROPRIATE COMPARATOR THERAPY FOR NEW DRUGS ON BENEFIT ASSESSMENT AND PRICING IN GERMANY
    Berger, I
    Richter, N.
    Martyniszyn-Eiben, A.
    Sake, S. M.
    Gluesen, M.
    Kielhorn-Schoenermark, H.
    Schoenermark, M.
    VALUE IN HEALTH, 2022, 25 (12) : S252 - S253
  • [8] CHALLENGES IN SELECTING RELEVANT COMPARATOR THERAPIES IN INDICATIONS WITH LOW EVIDENCE USING THE EXAMPLE OF GERMAN BENEFIT ASSESSMENTS WITH THE APPROPRIATE COMPARATOR THERAPY "TREATMENT OF PHYSICIANS CHOICE"
    Mattern, F.
    Bruns, C.
    Kovacevic, S.
    Eheberg, D.
    VALUE IN HEALTH, 2022, 25 (12) : S308 - S308
  • [9] Treatment response in hemato-oncology in the context of the German early benefit assessment of drugs compared to clinical practice
    Baltes, Nannette
    Icks, Andrea
    Dintsios, Charalabos-Markos
    JOURNAL OF EVIDENCE BASED MEDICINE, 2023, 16 (04) : 451 - 454
  • [10] RISK FACTORS FOR NOVEL PHARMACEUTICAL PRODUCTS OF BEING IMPOSED WITH A REGISTRY DURING THE GERMAN BENEFIT ASSESSMENT
    Buchholz, I. S. L.
    Ruedemann, N.
    Frick, L.
    Schoenermark, M. P.
    VALUE IN HEALTH, 2020, 23 : S708 - S708
12